LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche
By Stephen Nakrosis
LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche.
Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting, who were named joint administrators the LumiraDx Group and LumiraDx International subsidiaries, signed a definite agreement for the sale of "certain companies of the LumiraDx group engaged in its point of care diagnostics platform business and certain related assets," the company said.
Under the terms of the deal, Roche will pay a purchase price of $295 million and up to $55 million more "for the reimbursement of amounts to fund the point of care diagnostics platform business until the closing of the acquisition," LumiraDx said. The deal is expected to close in mid-2024.
The company said the appointment of the administrators and the sale to Roche are the culmination of its previously announced strategic review led by Goldman Sachs.
LumiraDx expects all sales proceeds will be used to repay certain amounts of the company's senior secured loan agreement, with no proceeds being distributed to shareholders or the company, it said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 29, 2023 16:52 ET (21:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?